Prognose

Das durchschnittliche Kursziel der Analysten beträgt +83,54€(−5,90%). Der Median liegt bei +86,39€(−2,69%).

Scoring-Modelle

Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research
Calgary, Alberta--(Newsfile Corp. - November 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce it has been awarded the Alberta Innovates AICE Validates grant, securing $300,000 in funding to support the preclinical validation of MB204 as a treatment for Alzheimer's disease. This funding represents a significant step forward for Marvel, providing the resources and recognition needed to advance toward clinical trials.» Mehr auf newsfilecorp.com
Chip stocks: What sets Marvell Technology apart from ASML
While Wall Street patiently awaits Nvidia's (NVDA) third quarter earnings due out this Wednesday, what are other viable semiconductor stocks for investors seeking to explore the industry? Spear Invest Founder and CIO Ivana Delevska joins Julie Hyman on Yahoo Finance's Good Buy or Goodbye to talk about these two chip stocks: Marvell Technology (MRVL) and ASML Holding (ASML).» Mehr auf youtube.com
Marvell Technology (MRVL) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Marvell Technology (MRVL) closed at $90.70, indicating a +0.7% shift from the previous trading day.» Mehr auf zacks.com

In 2022 hat MARVELL TECH GROUP 0,0534€ Dividende ausgeschüttet. Die letzte Dividende wurde im Januar 2022 gezahlt.

Im letzten Quartal hatte MARVELL TECH GROUP einen Umsatz von 1,17 Mrd€ und ein Nettoeinkommen von −177,01 Mio€